Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | OSBP | P22059 | 3/20 | 0.41 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.41 |
| ▸ | GPR183 | P32249 | 5/20 | 0.39 |
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.39 |
| ▸ | CRYAB | P02511 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911035 | 1.00 | CDC25A (0.49) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL14005478 | 1.00 | CDC25A (0.49) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL4899038 | 1.00 | CDC25A (0.49) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL13392701 | 0.92 | CDC25A (0.56) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL3221542 | 0.92 | CDC25A (0.56) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL14005400 | 0.89 | OSBP (0.39) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL16317442 | 0.89 | CDC25A (0.52) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL4896078 | 0.83 | CDC25A (0.48) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL4896073 | 0.83 | CDC25A (0.48) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL14005425 | 0.83 | CDC25A (0.48) | CDC25ACDC25BOSBPOSBP2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080280860-A1 | Use of Vitamin D Compounds to Treat Endometriosis | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| US-20070054887-A1 | Methods for treating bladder dysfunction | BIOXELL S.P.A (IT) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | VDR, GC, CYP24A1 | CDC25A 2295/4885CDC25B 2421/4885OSBP 1841/4885 |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | VDR, CYP24A1, CYP27B1 | CDC25A 110/4885CDC25B 107/4885OSBP 3126/4885 |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | VDR, CYP24A1, CYP2R1 | CDC25A 1832/4885CDC25B 1833/4885OSBP 2763/4885 |
| US-20080280860-A1 | Use of Vitamin D Compounds to Treat Endometriosis | VDR, CYP24A1, CYP2R1 | CDC25A 2029/4885CDC25B 2271/4885OSBP 623/4885 |
| US-20070054887-A1 | Methods for treating bladder dysfunction | CYP27B1, CYP24A1, VDR | CDC25A 3163/4885CDC25B 2889/4885OSBP 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.